GlassScriptPhysician profile
Amanda Lively
NPI 1982064622
$2,534.81
in general payments reported to CMS, 2019-2025
34 companies · $847 in 2025
The $847 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.53 · 2022: $485 · 2023: $603 · 2024: $578 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $669.15 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $475.21 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $159.34 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $146.90 | 2022 | |
| Pfizer INC. | $113.77 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $84.60 | 2021-2025 | Capvaxive, Vaxelis, Gardasil 9 |
| Amgen INC. | $72.08 | 2023-2025 | Evenity, Prolia, Prolia |
| Amneal Pharmaceuticals LLC | $56.95 | 2023 | Rytary |
| Xeris Pharmaceuticals, INC. | $54.43 | 2023 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $44.68 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $43.88 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $38.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.91 | 2023-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $35.06 | 2022-2025 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $32.82 | 2021-2025 | Nexplanon |
| Biogen, INC. | $25.86 | 2025 | Skyclarys |
| Lundbeck LLC | $25.83 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $25.70 | 2025 | |
| Boston Scientific Corporation | $25.11 | 2024 | Watchman Access System |
| Neurocrine Biosciences, INC. | $21.59 | 2025 | |
| Astellas Pharma US INC | $21.26 | 2024 | Veozah |
| Mylan Specialty L.P. | $20.32 | 2023 | Yupelri |
| Collegium Pharmaceutical, INC. | $19.57 | 2023 | Xtampza |
| Sanofi Pasteur INC. | $19.28 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.75 | 2024 | Xarelto |
| Inspire Medical Systems, INC. | $18.57 | 2025 | Inspire |
| Dexcom, INC. | $18.09 | 2022 | |
| Sumitomo Pharma America, INC. | $17.82 | 2025 | Gemtesa |
| Harmony Biosciences LLC | $17.54 | 2024 | |
| Medtronic, INC. | $17.21 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.54 | 2025 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $15.21 | 2024 | Voquezna |
| Globus Medical, INC. | $15.12 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.